White House Secures Final Drug Pricing Deal with Regeneron to Lower Costs
Updated
Updated · NOTUS · Apr 23
White House Secures Final Drug Pricing Deal with Regeneron to Lower Costs
54 articles · Updated · NOTUS · Apr 23
The White House has announced a drug pricing agreement with Regeneron, the last major pharmaceutical company to join President Trump's most-favored-nation initiative.
Regeneron will lower prices for its drugs on Medicaid and sell its cholesterol drug Praluent for $225 via the TrumpRx website.
This move aims to align U.S. drug prices with those in other developed countries and could reduce costs for both patients and state Medicaid budgets.
Will President Trump's drug pricing deals actually lower your healthcare costs?
How will new tariffs on imported medicine reshape the U.S. drug supply?
How do these deals compare to Medicare's own drug price negotiations?
Does the TrumpRx portal offer real savings or just repurposed discounts?
Are pharma companies offsetting these discounts by raising other drug prices?
Is a new gene therapy for hearing loss truly free for all in need?